|Day Low/High||33.44 / 34.45|
|52 Wk Low/High||27.88 / 43.08|
I see no reason to flee this name, therefore, I am not.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
Pfizer is a quality dividend stock that's now trading at a discount.
Pent-up demand for parties could give this seller of party goods a shot in the arm if Covid-19 abates, though it isn't a buy-and-hold prospect.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
The prices of hotels and even beaten up retailers say that many believe a vaccine is on the way -- here's how I would get positioned.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Also, several scheduled events this week, election risk, earnings to watch.
The 10-year U.S. note auction was soft. The yield of 0.704% was above the when issued of about 0.695%. The bid to cover of 2.30 was below the 12 month average of 2.47. Also, dealers were left with 27% of the auction vs. the one year average of 25%. ...
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
Plus, picking up dinged shares among Thursday's wreckage in the tech sector.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
How September markets digest August ahead of momentous events will be far more important to uptrend maintenance than how August closed.
Apple's weight in the (price-weighted) Dow Jones Industrial Average, effective this morning, will be reduced from 12% to 3% -- based on the company's 4-1 stock split. In response to that split, Amgen , Honeywell , and Salesforce are being added to t...
Plus, Veeva Systems reports stellar results and ups its guidance.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Let's check the charts as this biotech replaces Pfizer on the DJIA.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
Getting dropped from the Dow may give PFE the catalyst it needs to make a big move one way or the other.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Here's my 'counterintuitive' bet on lower Treasury prices, and therefore higher rates, right now.
What I see: This stock responds well to economic recovery.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
"I am going to write a good Diary on Real Money Pro today... and I am going to help people. Because I am good enough, I am smart enough and doggone it, people like me." - Daily Affirmations with Dougie Kass Today's Affirmations is about fame and how...
Let's check out the latest charts and indicators to plot a technical strategy.
The equity market recovery is just as sloppy in performance as the economy itself.
The headline numbers don't present the full story of what is going on with the equity markets.
Plus, quick looks at Joe Biden's VP choice, the latest on the Covid-19 vaccine front and Tesla's stock split.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
BMY sees reason for optimism over the final half of the year.